phosphatase/유방암

1. Test population: Patients with stage III gastric cancer confirmed by postoperative pathology 2. Sample size calculation: single arm design was used in this study, and the main outcome was progression free survival. In this study, PD-L1 + CPS ≥ 10% / MSI-H + / EB +, the sample size was estimated

PRIMARY OBJECTIVE: I. To determine if the combination of radium Ra 223 dichloride (radium-223 dichloride) and paclitaxel improves progression-free survival (PFS) compared to paclitaxel alone. SECONDARY OBJECTIVES: I. To determine the time to the first symptomatic skeletal event [SSE] (defined as 1st

OUTLINE: Patients are randomized to 1 of 3 arms. Arm I: Patients receive binimetinib orally (PO) twice daily (BID) for a lead-in period of 15 days in the absence of disease progression or unacceptable toxicity. Patients then receive binimetinib orally (PO) twice daily (BID) on days 1-28 and avelumab

3.4.1 Pharmaceutical and Therapeutic Background The importance of intact immune surveillance in controlling outgrowth of neoplastic transformation has been known for decades. Accumulating evidence shows a correlation between tumor-infiltrating lymphocytes (TILs) in cancer tissue and favorable

Introduction Borderline Ovarian Tumors (BOTs) behave indolently in the vast majority of cases and the prognosis is usually favorable. There is more evidence that two subtypes of BOTs represent a higher risk of recurrence or even progression to an invasive ovarian cancer. In case of a presentation

This is A Phase III, randomized, two-armed, patient-outcome assessor-data analyzer blinded, parallel active controlled non-Inferiority clinical trial study to evaluate efficacy and safety of AryoTrust (Aryogen Trastuzumab) in comparison to Herceptin® (Genentech/Roche) in patients with Human

PRIMARY OBJECTIVES: I. To determine a safe dose of niraparib when combined with radium Ra 223 dichloride (radium-223) in patients with metastatic castrate-resistant prostate cancer (mCRPC) that have and have not received prior chemotherapy. SECONDARY OBJECTIVES: I. To determine the proportion of

Background: - Primary gliomas are an incurable disease in spite of aggressive multimodality therapy consisting of craniotomy, irradiation, and chemotherapy. Therapeutic options for patients with recurrent glioma are limited, and there is an unmet need to identify more effective agents. - LB100, a

The FG-3019 treatment will be administered over a 28-day cycle: - Dose: 35 mg/kg - Route: IV over one hour following completion of gemcitabine infusion - Schedule: - Days 1, 8, and 15 - Please note that Day 8 infusion will on be completed during the first treatment cycle On Drug Evaluation The

1. Background During the past 30 years, survival of breast cancer patients has improved substantially due to earlier diagnosis, improved surgical techniques, introduction of new combination of chemotherapy, new hormonal treatment, introduction of targeted treatment, and refinement of radiation

Multiple Myeloma (MM) is a B cell malignancy characterized by the presence of bone marrow infiltration by clonal plasma cells that generally secrete a monoclonal component in the serum or urine. It is the second most frequent hematological malignancy, after non-Hodgkin lymphomas, and accounts

At present, the novel cheap and effective intervention against menopause related symptoms such as memory impairment and osteoporosis is still required due to the increased breast cancer risk induced by hormone replacement therapy. Based on the role of oxidative stress on cognitive deficit in

The purpose of this study was to evaluate the effectiveness of supplementation with 3,3´-Diindolylmethane (DIM) to increase the urinary ratio of estrogen metabolites 2OHE1:16alphaOHE1 (RMEU) in women at risk of breast cancer to contribute to generate a tool of early prevention of this

PRIMARY OBJECTIVES: I. To determine the safety and tolerability of taselisib given in combination with enzalutamide: Assessment of dose limiting toxicities (DLTs) during the first 4 weeks of treatment (cycle 1). (Phase Ib) II. To determine the safety and tolerability of taselisib given in

It has long been recognised that there is an association between chronic immune activation and cancer but the mechanisms behind this observation are not fully understood. The inflammatory process may provide an environment for development of malignant disease, with mediators of inflammatory response